Monday, 11 Nov 2019

You are here

Zolendronate Protects Against Fracture in Osteopenia

The NEJM reports that the use of zoledronate significantly reduces the risk of nonvertebral or vertebral fragility fractures in women with osteopenia.

While it is known that bisphonates have beneficial effects in osteoporosis, their impact in osteopenia has not been shown. 

A 6-year, double-blind trial involving 2000 elderly women (>65 yrs)  with osteopenia (T score −1.0 to −2.5)in the hip or femoral neck were randomized to receive four infusions of zoledronate (5 mg) or saline (placebo group) at 18-month intervals. The primary end point was the time to first occurrence of a nonvertebral or vertebral fragility fracture.

The baseline age was 71±5 years, T score was −1.6±0.5, and the 10-year risk of hip fracture was 2.3%.

A fragility fracture occurred in 190 women in the placebo group and in 122 women in the zoledronate group (hazard ratio with zoledronate, 0.63; 95% confidence interval, 0.50 to 0.79; P<0.001).

The NNT to prevent a fracture in 1 woman was 15.

Women treated with zoledronate had a lower risk of nonvertebral fragility fractures (hazard ratio, 0.66), symptomatic fractures (HR 0.73), vertebral fractures (OR 0.45) and height loss (P<0.001).

The bisphosphonate, zoledronate (zoledronic acid) is marketed by Novartis under the of Reclast.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Physical Activity Lowers Fracture Risk in Post-Menopausal Women

An analysis from the Women’s Health Initiative study shows that postmenopausal women who participate in vigorous physical activity have a statistically lower risk of total and site-specific fractures

High Dose Statins Increase Odds of Osteoporosis

It is unknown if inhibiting cholesterol synthesis (with statins) might influence sex-hormone production and therefore, the risk of osteoporosis. A new study shows that, in statin-treated individuals, the development of osteoporosis is statin dose-dependent.

Sprifermin Benefits Cartilage Loss but not Symptoms in Knee Osteoarthritis

Intra-articular sprifermin given to patients with symptomatic and radiographic knee osteoarthritis has been shown to significantly improve total femorotibial joint cartilage thickness after 2 years, but without significant clinical benefits. Which begs the question, why is there a disconnect between radiographic disease modification (cartilage thickness) and symptomatic improvement?

Bisphosphonates and the Risk of Osteonecrosis of the Jaw

Even though oral bisphosphonates are widely used, there is an inordinate concern over the risk of osteonecrosis of the jaw (ONJ). A new UK study suggests that the risk of ONJ is elevated six fold by the use of biphosphonates.

ASBMR Recommendations on Secondary Fracture Prevention

The American Society for Bone and Mineral Research has developed multistakeholder consensus clinical recommendations for the prevention of secondary fractures for those aged 65 years and older after an initial hip or vertebral fracture.

Overall they have promoted 13 recommendations (7 primary and 6 secondary) strongly supported medical evidence.

Highlights include recommendations for: